2. Antibody-drug Conjugate/ADC Related GPCR/G Protein Neuronal Signaling
  3. Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor
  4. DOTA-LM3 TFA

DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

DOTA-LM3 TFA Chemical Structure

DOTA-LM3 TFA Chemical Structure

Size Price Stock Quantity
5 mg USD 320 In-stock
10 mg USD 500 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of DOTA-LM3 TFA:

DOTA-LM3 TFA Related Antibodies

Top Publications Citing Use of Products

View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

View All Isoforms
RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

View All Somatostatin Receptor Isoform Specific Products:

View All Isoforms
SSTR1 SSTR2 SSTR3 SSTR5 SSTR4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis[1][2].

IC50 & Target

RDC Peptide

 

In Vitro

177Lu-DOTA-LM3 TFA is tolerated. 177Lu-DOTA-LM3 TFA in the whole body and in the kidneys, spleen, and metastases, resulting in higher mean absorbed organ and tumor doses[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DOTA-LM3 TFA Related Antibodies
Molecular Weight

1664.18

Formula

C71H94ClF3N16O21S2
Appearance

Solid

Color

White to off-white

Sequence

DOTA-[p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH2]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility
In Vitro: 

H2O : 100 mg/mL (60.09 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.6009 mL 3.0045 mL 6.0090 mL
5 mM 0.1202 mL 0.6009 mL 1.2018 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.30%

SDS (252 KB)

COA (253 KB) LCMS (97 KB) Elemental Analysis Report (112 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 0.6009 mL 3.0045 mL 6.0090 mL 15.0224 mL
5 mM 0.1202 mL 0.6009 mL 1.2018 mL 3.0045 mL
10 mM 0.0601 mL 0.3004 mL 0.6009 mL 1.5022 mL
15 mM 0.0401 mL 0.2003 mL 0.4006 mL 1.0015 mL
20 mM 0.0300 mL 0.1502 mL 0.3004 mL 0.7511 mL
25 mM 0.0240 mL 0.1202 mL 0.2404 mL 0.6009 mL
30 mM 0.0200 mL 0.1001 mL 0.2003 mL 0.5007 mL
40 mM 0.0150 mL 0.0751 mL 0.1502 mL 0.3756 mL
50 mM 0.0120 mL 0.0601 mL 0.1202 mL 0.3004 mL
60 mM 0.0100 mL 0.0501 mL 0.1001 mL 0.2504 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DOTA-LM3 TFA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DOTA-LM3Radionuclide-Drug Conjugates (RDCs)Somatostatin ReceptorSSTRsSSTRsomatostatin receptorLM3p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2sotopically labeled177Lu-DOTA-LM368 Ga-DOTA-LM3biodistributionhigh tumor uptakegood tumor retentionsafetyDOTATOC-negative liver metastasespancreatic NETextensive tumor thrombosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DOTA-LM3 TFA
Cat. No.:
HY-P5126A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.